Journal of Experimental & Clinical Cancer Research

Table 1 The expression of Nek2B and β-catenin with clinicopathological features in TNBC patients

From: Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin

Factors		Nek2B P				β-catenin P
		Positive		negative		Positive		negative
		N	%	N	%	N	%	N	%
All	174	116	66.7	58	33.3	150	86.2	24	13.8
Age					0.824				0.197
≤ 50	110	74	67.3	36	32.7	92	83.6	18	16.4
>50	64	42	65.6	22	34.4	58	90.6	6	9.4
Tumor size (cm)					0.033^a				0.975
≤ 2	26	14	53.8	12	46.2	24	92.3	2	7.7
>2; ≤ 5	96	72	75.0	24	25.0	82	85.4	14	14.6
>5	52	30	57.7	22	42.3	44	84.6	8	15.4
Tumor grade					< 0.0001^a				0.593
G1-G2	64	24	37.5	40	62.5	54	84.4	10	15.6
G3	110	92	83.6	18	16.4	96	87.3	14	12.7
LNs metastasis					0.003^a				0.191
No	80	44	55.0	36	45.0	66	82.5	14	17.5
Yes	94	72	76.6	22	23.4	84	89.4	10	10.6
Ki67					< 0.0001*				0.003^a
<20%	82	42	51.2	40	48.8	64	78.0	18	22.0
≥ 20%	92	74	80.4	18	19.6	86	93.5	6	6.5
β-catenin					0.001^a
Negative	24	8	33.3	16	66.7	–		–
Positive	150	108	72.0	42	28.0	–		–
Radiotherapy					0.782				0.814
No	142	94	66.2	48	33.8	122	85.9	20	14.1
Yes	32	22	68.8	10	31.3	28	87.5	4	12.5
Chemotherapy					0.646				0.897
No	56	36	64.3	20	35.7	48	85.7	8	14.3
Yes	118	80	67.8	38	32.2	102	86.4	16	13.6

LNs Lymph nodes; ^aDifference was statistically significant

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com